Skip to main content
padlock icon - secure page this page is secure

Antidepressants: Update on Benefits and Risks

Buy Article:

$68.00 + tax (Refund Policy)

Since the initial discovery of the first antidepressants in the 1950s, at least two generations of these medications have come to market. Following a brief historical introduction, this paper reviews the first- and second-generation (FGA and SGA) antidepressant medications and their class-related and individual side effect profiles. Class-related adverse reactions include dietary interactions of monoamine oxidase inhibitors (MAOIs) with tyramine, cardiovascular toxicities of the FGAs, and the behavioral syndrome and sexual dysfunction produced by selective serotonergic reuptake inhibitors (SSRIs). Adverse effects common to the different classes include discontinuation syndromes, possible cognitive impairment, suicidality, and a variety of cardiovascular, gastrointestinal and motoric disturbances. Recent reports of side effects elicited by specific agents are noted. Current concerns raised by antidepressant use in pregnancy are discussed. Recent criticisms of the effectiveness claims of antidepressants are summarized. These include the significant placebo contribution to antidepressant outcomes and the ongoing debate about the long-term usefulness of psychotropic medications in general. Most relevant to antidepressants is the recently proposed phenomenon of “tardive dysphoria” that may occur after prolonged antidepressant use and promote resistance to further treatment.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antidepressants; Insomnia; Tyramine; Venlafaxine; citalopram; first generation antidepressants; fluoxetine; mirtazapine; monoamine oxidase inhibitors; obsessive-compulsive disorder (OCD); second generation antidepressants; selective serotonin reuptake inhibitors; serotoninnorepinephrine reuptake inhibitor; side effects; tamoxifen

Document Type: Research Article

Publication date: August 1, 2012

More about this publication?
  • Current Psychopharmacology publishes peer-reviewed expert review articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology. Data must be published for the first time in Current Psychopharmacology.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more